About this trial
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of BPDCN
Signed informed consent form for prospective patients
Disqualifiers
None
Trial population
All patients with BPDCN diagnosed since 01.01.2010
Trial design
Case-only
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Overall survival
Time from diagnosis to death
Secondary outcomes
Complete remission rate
The proportion of patients with complete remission
Mean duration of the first remission
Time from first remission to disease progression or death
Event-free survival
Time from diagnosis to occurrence of a complication
Sponsors and contacts
Click on the lead sponsor to view all of their trials.